Abstract: The present invention provides compositions and methods for the treatment of neurological disorders. In particular, the present invention can be used for treating and/or preventing the symptoms and/or comorbidities of neurodegenerative conditions, diseases or disorders, such as, for example, Alzheimer's and Parkinson's disease.

Abstract: The present invention includes methods of monitoring measurable residual disease in patients suffering from a proliferative disorder, determining which patients could benefit from treatment or intervention with crenolanib or salt in reducing residual disease and maintaining remission, and administering a therapeutically effective amount of crenolanib as a single agent or sequentially or concomitantly with another therapeutic agent.

Abstract: Compounds described herein are mithramycin (MTM) oxide (OX) derivatives and MTM Hydrazine (HY) derivatives. These compounds are useful for treatment of cancers and neuro-diseases.

Abstract: The present invention relates to a composition for viral RNA extraction and a viral RNA extraction method using the same, wherein various contaminants (e.g., fungi, bacteria, pollens, etc.) can be effectively removed from samples and thus the diagnosis of sample-derived viruses can be attained more sensitively, and more cheap reagents compared with existing compositions for RNA extraction are used and thus the scales of diagnosis tests of disease-mediated viruses and various monitoring programs can be further enlarged, thereby contributing to public health.

Abstract: The disclosure provides a CD169 high affinity anti-tumor compound (TCC-Neu5A) and its preparation and application. The CD169 high affinity anti-tumor compound is a small molecule compound, which has specific and broad-spectrum tumor killing characteristics. TCC-Neu5Ac could targets tumor cells in vivo and metabolize onto a surface of the tumor cells to form CD169 ligands. These tumor cells are recognized and phagocytized by CD169-positive macrophages, which then release tumor-related antigens and present them to other immune cells, triggering an anti-tumor immune response. The CD169 high affinity anti-tumor compound provided by the disclosure is effective for a variety of tumors and has an inhibitory effect on tumor metastasis. In addition, the CD169 high affinity anti-tumor compound provided by the disclosure can not only be injected but also be orally administered. Cytotoxicity and animal toxicity of the CD169 high affinity anti-tumor compound are very low.

Abstract: A packaging system for the storage of an ophthalmic device includes a sealed container containing one or more unused ophthalmic devices immersed in an aqueous packaging solution comprising one or more crosslinked polymeric networks. The one or more crosslinked polymeric network comprises a reaction product of a first glycosaminoglycan, a second glycosaminoglycan, and a first crosslinking agent, wherein the first glycosaminoglycan is different than the second glycosaminoglycan. The aqueous packaging solution has an osmolality of at least about 180 mOsm/kg, a pH of about 6 to about 9 and is heat sterilized.

Abstract: Aspects of the invention provide compositions for use in the treatment galectin-dependent diseases. In particular, compositions comprising a selectively depolymerized, branched galactoarabino-rhamnogalacturonate whose backbone is predominantly comprised of 1,4-linked galacturonic acid (GalA) moieties, with a lesser backbone composition of alternating 1,4-linked GalA and 1,2-linked rhamnose (Rha), which in-turn is linked to any number of side chains, including predominantly 1,4-b-D-galactose (Gal) and 1,5-a-L-arabinose (Ara) residues.

Abstract: Embodiments of the invention are directed to new equatorially modified polymer linked multimers of guanosine-3?, 5?-cyclic monophosphate (cGMP) analogues that inhibit the cGMP-signaling system. The invention is also directed to related monomeric compounds, which may serve as monomeric precursors of the multimers, and/or also show itself inhibitory activity and/or impact the inhibitory activity of the related multimers. The invention further relates to the use of such compounds as reagents for signal transduction research and as modulators of cyclic nucleotide-regulated binding proteins and isoenzymes thereof, and as ligands for affinity chromatography, for antibody production or for diagnostic applications, e.g., on chip surfaces.

Abstract: The present disclosure relates to phosphorylated hexaacyl disaccharide (PHAD) compounds, compositions, and methods for treating or preventing infections.

Abstract: The present invention concerns cobalamin derivatives of formula (I) wherein X is a ligand having a formula selected from among: —(CH2)1-5—S—(CH2)0-3—CH3, —S—(CH2)1-5—NH2 and further wherein R1 is H, methyl or ethyl, R2 is and R3 is —H or and its use in diseases caused by lack of vitamin B12 support.

Abstract: Provided herein are compositions and methods to improve treatment of chronic infections, and reduce, delay, or inhibit formation of biofilms, using specific combinations of aminoglycoside antibiotics and treatment with one or more proton motive force (PMF) stimulating compounds. These novel methods are easily adapted to clinical settings as toxicity and efficacy of the antibiotics and metabolites used have already been studied in vivo, and as dosing for both the antibiotics and metabolites are known.

Abstract: The invention discloses a myrtle polysaccharide P1, the separation method thereof and the use in preparing hypolipidemic drugs therefor, wherein the P1 contains 6.74% of ribose, 1.73% of rhamnose, 60.06% of arabinose, 3.54% of xylose, 5.64% of mannose, 13.16% of glucose, and 9.13% of galactose. The experiment result shows that the myrtle polysaccharide P1 has a certain ability to bind cholate in vitro. Taking cholestyramine as a positive control and the binding rate of cholestyramine to each cholate as 100%, the relative binding rate of the myrtle polysaccharide P1 to sodium taurocholate, sodium glycocholate and sodium cholate was 25.28%, 44.56%, and 50.10%, respectively.

Abstract: An object of the present invention is to provide an anti-tumor agent and an anti-tumor kit which have superior anti-tumor effect as compared with a therapy with gemcitabine, paclitaxel or a combination thereof; as well as an anti-tumor effect enhancer. According to the present invention, provided is an anti-tumor agent including paclitaxel or a salt thereof and 1-(2-deoxy-2-fluoro-4-thio-?-D-arabinofuranosyl)cytosine or a salt or prodrug thereof.

Abstract: Problem: A malaria transmission blocker or a malaria parasite growth inhibitor is provided as a result of finding a druq which inhibits malaria parasite growth in the body of a vector mosquito. Solution: A malaria parasite growth inhibitor or transmission blocker containing a rare sugar such as D-allose or D-psicose as an active ingredient.

Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

Abstract: The present disclosure discloses a method for extracting a RG-I-rich pectic polysaccharide. The method comprises the following steps: mixing and stirring a citrus fruit peel powder and a dilute hydrochloric acid solution at a low temperature to destroy cell walls of citrus peels, filtering, and then mixing the retentate with a sodium hydroxide solution for low temperature extraction, adding ethanol to the solution obtained by filtering to precipitate, and washing the obtained polysaccharide with ethanol and drying to obtain the above pectic polysaccharide. Compared with the traditional extraction method, this method reduces the hydrolysis of pectin side chains by controlling the extraction temperature, and the extracted pectic polysaccharide is rich in RG-I domain and has higher biological activity such as cancer and cardiovascular disease prevention. Energy can be greatly saved because of the low extraction temperature.

Abstract: The invention relates to a composition comprising one or more human milk oligosaccharides (HMOs) for use in stimulating the production of butyrate in the gastro-intestinal tract of a non-infant human and obtaining delayed increase in the level of butyrate in the gastro-intestinal tract of the non-infant human, and methods for their use.

Abstract: New methods for treating and/or preventing cardiovascular disease including, for example, myocardial infarction and atherosclerosis, by the use of at least one E-selectin inhibitor and compositions comprising the same are disclosed.

Abstract: The present invention disclosed herein provides synergistic nutritional neuroprotective compositions for ameliorating neural dysfunction. Particularly, the invention relates to synergistic, efficient, nutritional composition for comprising specific combination of decarboxylated L-arginine called agmatine sulphate and nicotinamide riboside chloride, wherein agmatine sulphate and nicotinamide riboside chloride are present in the weight ratio of 1:0.05 to 1:2 along with pharmaceutically acceptable excipients. More particularly, the present invention offers synergistic effect for ameliorating neural dysfunction encompasses cerebrovascular diseases, neurodevelopmental disorders, mood disorders, mental health disorders and like thereof.

Abstract: The present disclosure relates to compounds and compositions for use in treating disease, such as viral infection. As disclosed herein, the compounds include an “NMN-like” moiety linked to another moiety with biological activity upon administration. In some cases, the disease to be treated is infection with viruses. Such viruses include coronaviruses, such as SARS, MERS, or COVID-19, HIV, and viruses associated with hepatitis. Further, the invention relates to methods of using such compounds or compositions to promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD) in cells and tissues for treating diseases and/or improving cell and tissue survival.